Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 October 2025 | Story Tshepo Tsotetsi | Photo Kaleidoscope Studios
EDSA Prestige Awards
From left: Dr Temba Hlasho, Executive Director: Student Affairs; Jane Mpholo, 2025 Student of the Year; and Prof Noluxolo Gcasa, Guest Speaker, at the 2025 EDSA Prestige Awards.

The Division of Student Affairs at the University of the Free State (UFS) brought together students, staff, and senior management on Friday 24 October 2025 for the fourth edition of the Executive Director: Student Affairs (EDSA) Prestige Awards – an evening dedicated to recognising students whose leadership, creativity, and commitment are shaping a more inclusive university.

Held at the Bloemfontein Campus, the ceremony honoured outstanding students across all three campuses who have excelled through academic performance, community engagement, and innovation. From sport and residence life to student governance, counselling, health and wellness, social support, and the Centre for Universal Access and Disability Support, each award reflected the depth of student impact within the university community.

 

A night that belonged to students

Dr Temba Hlasho, Executive Director of Student Affairs, said the awards serve as a reminder of the values that underpin the UFS journey toward Vision 130. “By recognising and rewarding excellence,” he said, “we reinforce the culture of achievement and innovation that drives our students.”

He congratulated the winners for their perseverance, describing them as “dreamers who never give up” – borrowing the words of Nelson Mandela – and encouraged them to remain ambassadors of the university’s spirit of excellence.

Guest speaker Prof Noluxolo Gcaza, Associate Professor from Nelson Mandela University, reflected on the meaning of excellence in her keynote address. “Excellence is a way of being,” she said. “It’s not about recognition at the end – it’s the fruit of your quiet perseverance. Whether your name is called or not, your contribution adds to the living story of this university.”

The highlight of the evening was the announcement of the EDSA Student of the Year, celebrating students who embody global citizenship, academic distinction, leadership, and community engagement.

Jane Mpholo-Mehlape, an Honours in Drama and Theatre Arts student specialising in Theatre for Young Audiences and Directing, earned the top honour. A multi-award-winning theatre-maker, filmmaker, and social entrepreneur, she uses the performing arts to confront social issues, create employment, and mentor young people.

“It feels surreal,” she said after receiving her award. “For years I’ve poured everything into my work, so this recognition affirms that what I’m doing matters… that we are seen.”

Coming from the performing arts, she added, the recognition carries special weight. “People often see performance as just entertainment,” she said. “But art can give people voices and opportunities. This award recognises leadership, transformation, and community – and those are everything that I am.”

Joining her were Thabang Mahlangu, a Human Resource Management student and member of the Shimlas rugby team, who received the first runner-up honours for his contributions to sport, leadership, and community engagement, and Mbalenhle Thungo, a Bachelor of Administration student from the Qwaqwa Campus, who was named second runner-up. Thungo is an entrepreneurial student leader serving as the Deputy Chairperson of the Faculty of Economic and Management Sciences Student Council.

Together, the winners represent the diverse ways in which UFS students continue to demonstrate excellence: not as a goal, but as a way of being that reflects the heart of the institution.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept